A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors

NCT04866836 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

20

Enrollment

OTHER

Sponsor class

Stopped The study was prematurely terminated due to difficulties in recruitment.

Conditions

Cholangiocarcinoma

Interventions

COMBINATION_PRODUCT: Radiotherapy

Sponsor

The First Affiliated Hospital with Nanjing Medical University